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Decreased Pain Severity and Differential Gene Expression Following Calmare Therapy
Amy Heineman, BSN, RN, STAR Project Director, Jeffrey B. Petraco, MBA, RN and Angela Starkweather, Ph.D., ACNP-BC, CNRN,
Associate Professor and Chair, Adult Health and Nursing Systems Department

Abstract
We present the results of a double-blinded randomized shamcontrolled research study of a non-pharmacologic low back pain
intervention. Calmare therapy is an neurocutanous electrical
stimulation approach for pain management. The intervention group
received Calmare therapy and the other received sham. Differences
in pain severity and interference scores, pain sensitivity measures and
gene expression profiles are reported. Patterns of downregulated
gene expression suggest that Calmare may alter proteins involved in
pain transduction may have implications for the treatment of other
chronic pain conditions.

Introduction
 Persistent low back pain (LBP) is one of the nation’s most
expensive medical conditions and a leading cause of disability.
 Several lines of evidence support the premise that LBP develops
as a consequence of sensitization of nociceptors and neuronal
circuits with modifications in the expression of genes that
encode pain signaling molecules and their receptors.
 Gene associated with neurotropins, inflammatory mediators and
catecholamines are most often modified.
 Calmare, a non-invasive bioengineering-based method of pain
treatment, was designed to interrupt the mechanisms of
persistent pain by scrambling the pain signaling using electrical
waveforms that mimic endogenous action potentials.
 A double–blinded randomized sham controlled pilot study was
conducted at VCU School of Nursing. Persistent LBP was
defined as pain without a specific cause or need for surgical
intervention in the region of the low back below T2 and above
the buttock crease, persistent for at least or more than 3
months for more than or equal to 4 days a week at a level of 4
or greater. Participants received a standard protocol of Calmare
or sham using the Calmare device to deliver a non-therapeutic
threshold. Data collected included study questionnaires,
quantitative sensory testing (QST), and blood samples.

Results/Discussion
There was a statistically significant difference in the “worst” pain score
between the Calmare and sham groups at the 1 and 3 week follow-up visits.
Pain interference was significantly different between groups at the 3 week
follow-up visit, with significantly lower pain interference in the Calmare
group. The “worst” pain and interference scores of the BPI showed a
significant decrease in the Calmare group from baseline to the 3 week
follow-up visit whereas the sham treatment group did not change over time.
In the Calmare group, 7 (47%) participants had a >50% reduction in the
“worst” pain score from baseline to the 3-week follow-up visit, 5 (33%)
participants had a 30-49% reduction, and 3 (20%) had a 20-29% reduction.
Measures of pain sensitivity (heat pain threshold, single stimulus rating,
and pressure pain threshold) were significantly different between groups at
the 3 week follow-up visit. The higher level thresholds to heat pain and
pressure pain in the Calmare group at 3 weeks follow-up reflect that a
higher stimulus intensity is required to cause a perception of pain.
Consistent with these findings, they also rated their perception of pain
lower to the single heat stimulus. These findings demonstrate less pain
sensitivity in the Calmare group compared to the sham group at the 3 week
follow-up visit. However, the within group changes in pain sensitivity
measures from baseline to 3 weeks did not reach a level of statistical
significance.
There were no significant differences in the baseline mRNA levels of the
84 candidate genes between the Calmare and sham groups. However,
differential expression of 17 candidate genes was observed between
baseline and 3 weeks post-intervention. Using a p-value threshold of <0.01,
the fold regulation of these genes were significantly different between the
Calmare and sham group: BDKRB1, CACNA1B, CCKBR, CHRNA4,
GDNF, GRM1, HTR2A, KCNIP3, KCNQ2, NGF, NTRK1, OPRD1, OPRK1,
OPRM1, PENK, PLA2G1B, and TAC1. The table below shows the
differential fold regulation in the Calmare group at 3 weeks postintervention accompanied by the associated p-value.
Differential Gene Expression in the Calmare Group at 3 Weeks Post-Treatment
Gene
BDKRB1
CACNA1B
CCKBR
CHRNA4
GDNF
GRM1
HTR2A
KCNIP3
KCNQ2
NGF
NTRK1
OPRD1
OPRK1
OPRM1
PENK
PLA2G1B
TAC1

Fold Regulation
-2.468
-1.518
-1.804
-1.924
-2.141
-1.715
-2.630
-2.587
-1.550
-2.599
-1.980
-1.812
-2.083
-1.699
-1.850
-1.816
-1.852

p-value
0.0069
0.0091
0.0150
0.0053
0.0036
0.0033
0.0100
0.0100
0.0172
0.0040
0.0035
0.0049
0.0110
0.0100
0.0042
0.0020
0.0150

Conclusion
The results of this study suggest that Calmare provides significantly
more pain relief than sham at 3 weeks post-intervention and can
reduce pain intensity, interference and pain sensitivity in individuals
with persistent low back pain. The differential expression of pain
genes between the intervention and sham group suggests that it may
exert an effect by downregulating pain receptors and proteins involved
in maintaining persistent pain. Evaluation of long-term outcomes after
Calmare, particularly functional status, analgesic use and health care
utilization, is warranted in future studies.
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